| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | MAKSCIENTIFIC | 151 S BEDFORD ST | BURLINGTON | MA | 01803-5228 | MIDDLESEX | USA | R44DK139888 | A CB1 Antagonist for Treatment of Kidney Disease | 000 | 1 | NIH | 11/6/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $572,743 ) |
| | 2024 | 2024 | MAKSCIENTIFIC | 151 S BEDFORD ST | BURLINGTON | MA | 01803-5228 | MIDDLESEX | USA | R44DK139888 | A CB1 Antagonist for Treatment of Kidney Disease | 000 | 1 | NIH | 8/26/2024 | $572,743 |
|
| Issue Date FY: 2023 ( Subtotal = $320,000 ) |
| | 2023 | 2023 | MAKSCIENTIFIC, LLC | 151 S BEDFORD ST STE 104-B | BURLINGTON | MA | 01803-5295 | MIDDLESEX | USA | R43DA057439 | Dual Fatty Acid Amide Hydrolase (FAAH)/Monoacylglycerol lipase (MAGL) Inhibitors for Cannabis Use Disorder (CUD). | 000 | 1 | NIH | 5/30/2023 | $320,000 |
| | 2023 | 2020 | MAKSCIENTIFIC | 151 S BEDFORD ST | BURLINGTON | MA | 01803-5228 | MIDDLESEX | USA | U18DA052537 | Dual Fatty Acid Amide Hydrolase (FAAH) and Monoacyglycerol Lipase (MAGL) Inhibitors as Novel Agents for Treatment of Cannabis Use Disorder (CUD) | 000 | 1 | NIH | 9/19/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2019 | MAKSCIENTIFIC, LLC | 151 S BEDFORD ST STE 104-B | BURLINGTON | MA | 01803-5295 | MIDDLESEX | USA | R41DK115303 | Lead Optimization of Peripheral CB1 Neutral Antagonists for Renal Diseases | 000 | 1 | NIH | 2/16/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2020 | MAKSCIENTIFIC, LLC | 151 S BEDFORD ST STE 104-B | BURLINGTON | MA | 01803-5295 | MIDDLESEX | USA | U18DA052537 | Dual Fatty Acid Amide Hydrolase (FAAH) and Monoacyglycerol Lipase (MAGL) Inhibitors as Novel Agents for Treatment of Cannabis Use Disorder (CUD) | 000 | 1 | NIH | 9/13/2021 | $0 |
| | 2021 | 2017 | MAKSCIENTIFIC, LLC | 151 S BEDFORD ST STE 104-B | BURLINGTON | MA | 01803-5295 | MIDDLESEX | USA | R44DK104636 | NAAA Inhibitors as Anti-inflammatory Agents, Phase II | 000 | 3 | NIH | 7/31/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $218,855 ) |
| | 2020 | 2020 | MAKSCIENTIFIC LLC | 151 SOUTH BEDFORD SREET, SUITE 104-B | BURLINGTON | MA | 01803-5228 | MIDDLESEX | USA | U18DA052537 | Dual Fatty Acid Amide Hydrolase (FAAH) and Monoacyglycerol Lipase (MAGL) Inhibitors as Novel Agents for Treatment of Cannabis Use Disorder (CUD) | 000 | 1 | NIH | 9/15/2020 | $218,855 |
| | 2020 | 2020 | MAKSCIENTIFIC LLC | 151 SOUTH BEDFORD SREET, SUITE 104-B | BURLINGTON | MA | 01803-5228 | MIDDLESEX | USA | U18DA052537 | Dual Fatty Acid Amide Hydrolase (FAAH) and Monoacyglycerol Lipase (MAGL) Inhibitors as Novel Agents for Treatment of Cannabis Use Disorder (CUD) | 001 | 1 | NIH | 9/21/2020 | $0 |
| | 2020 | 2019 | MAKSCIENTIFIC LLC | 151 SOUTH BEDFORD SREET, SUITE 104-B | BURLINGTON | MA | 01803-5228 | MIDDLESEX | USA | R41DK115303 | Lead Optimization of Peripheral CB1 Neutral Antagonists for Renal Diseases | 000 | 1 | NIH | 7/22/2020 | $0 |
| | 2020 | 2019 | MAKSCIENTIFIC LLC | 151 SOUTH BEDFORD SREET, SUITE 104-B | BURLINGTON | MA | 01803-5228 | MIDDLESEX | USA | R41DK115303 | Lead Optimization of Peripheral CB1 Neutral Antagonists for Renal Diseases | 001 | 1 | NIH | 8/24/2020 | $0 |
| | 2020 | 2017 | MAKSCIENTIFIC LLC | 151 SOUTH BEDFORD SREET, SUITE 104-B | BURLINGTON | MA | 01803-5228 | MIDDLESEX | USA | R44DK104636 | NAAA Inhibitors as Anti-inflammatory Agents, Phase II | 000 | 3 | NIH | 6/8/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $224,999 ) |
| | 2019 | 2019 | MAKSCIENTIFIC LLC | 151 SOUTH BEDFORD SREET, SUITE 104-B | BURLINGTON | MA | 01803-5228 | MIDDLESEX | USA | R41DK115303 | Lead Optimization of Peripheral CB1 Neutral Antagonists for Renal Diseases | 000 | 1 | NIH | 9/13/2019 | $224,999 |
| | 2019 | 2019 | MAKSCIENTIFIC LLC | 151 SOUTH BEDFORD SREET, SUITE 104-B | BURLINGTON | MA | 01803-5228 | MIDDLESEX | USA | R41DK115303 | Lead Optimization of Peripheral CB1 Neutral Antagonists for Renal Diseases | 001 | 1 | NIH | 9/13/2019 | $0 |
| | 2019 | 2017 | MAKSCIENTIFIC LLC | 151 SOUTH BEDFORD SREET, SUITE 104-B | BURLINGTON | MA | 01803-5228 | MIDDLESEX | USA | R44DK104636 | NAAA Inhibitors as Anti-inflammatory Agents, Phase II | 000 | 3 | NIH | 8/8/2019 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $646,219 ) |
| | 2017 | 2017 | MAKSCIENTIFIC LLC | 151 SOUTH BEDFORD SREET, SUITE 104-B | BURLINGTON | MA | 01803-5228 | MIDDLESEX | USA | R44DK104636 | NAAA Inhibitors as Anti-inflammatory Agents, Phase II | 000 | 3 | NIH | 8/22/2017 | $646,219 |
| | 2017 | 2015 | MAKSCIENTIFIC LLC | 151 SOUTH BEDFORD SREET, SUITE 104-B | BURLINGTON | MA | 01803-5228 | MIDDLESEX | USA | R43DK104636 | NAAA Inhibitors as Anti-Inflammatory Agents | 000 | 1 | NIH | 8/15/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $646,219 ) |
| | 2016 | 2016 | MAKSCIENTIFIC LLC | P.O. BOX 184 | WEST MYSTIC | CT | 06388-0184 | SOUTHEASTERN CT | USA | R44DK104636 | NAAA Inhibitors as Anti-inflammatory Agents, Phase II | 000 | 2 | NIH | 9/23/2016 | $646,219 |
| | 2016 | 2015 | MAKSCIENTIFIC LLC | PO BOX 184 | WEST MYSTIC | CT | 06388 | SOUTHEASTERN CT | USA | R43DK104636 | NAAA Inhibitors as Anti-Inflammatory Agents | 000 | 1 | NIH | 10/21/2015 | $0 |
| | 2016 | 2015 | MAKSCIENTIFIC LLC | PO BOX 184 | WEST MYSTIC | CT | 06388 | SOUTHEASTERN CT | USA | R43DK104636 | NAAA Inhibitors as Anti-Inflammatory Agents | 001 | 1 | NIH | 9/22/2016 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $239,541 ) |
| | 2015 | 2015 | MAKSCIENTIFIC LLC | P.O. BOX 184 | WEST MYSTIC | CT | 06388-0184 | SOUTHEASTERN CT | USA | R43DK104636 | NAAA Inhibitors as Anti-Inflammatory Agents | 000 | 1 | NIH | 4/1/2015 | $232,633 |
| | 2015 | 2014 | MAKSCIENTIFIC LLC | P.O. BOX 184 | WEST MYSTIC | CT | 06388-0184 | SOUTHEASTERN CT | USA | R43DA036982 | Cannabinergic Receptor Antagonists for Nicotine Addiction | 000 | 1 | NIH | 10/16/2014 | $6,908 |
|
| Issue Date FY: 2014 ( Subtotal = $214,936 ) |
| | 2014 | 2014 | MAKSCIENTIFIC LLC | P.O. BOX 184 | WEST MYSTIC | CT | 06388-0184 | SOUTHEASTERN CT | USA | R43DA036982 | Cannabinergic Receptor Antagonists for Nicotine Addiction | 000 | 1 | NIH | 5/30/2014 | $214,936 |
| | 2014 | 2011 | MAKSCIENTIFIC LLC | PO BOX 184 | WEST MYSTIC | CT | 06388 | SOUTHEASTERN CT | USA | R44DA023737 | New Drugs to Enhance Endocannabinoid Responses for Treating Excitotoxicity, Phase | 000 | 3 | NIH | 11/14/2013 | $0 |
|
| Issue Date FY: 2013 ( Subtotal = $0 ) |
| | 2013 | 2011 | MAKSCIENTIFIC LLC | PO BOX 184 | WEST MYSTIC | CT | 06388 | SOUTHEASTERN CT | USA | R44DA023737 | New Drugs to Enhance Endocannabinoid Responses for Treating Excitotoxicity, Phase | 000 | 3 | NIH | 11/9/2012 | $0 |
|
| Issue Date FY: 2011 ( Subtotal = $516,628 ) |
| | 2011 | 2011 | MAKSCIENTIFIC LLC | P.O. BOX 184 | WEST MYSTIC | CT | 06388-0184 | SOUTHEASTERN CT | USA | R44DA023737 | New Drugs to Enhance Endocannabinoid Responses for Treating Excitotoxicity, Phase | 000 | 3 | NIH | 1/6/2011 | $516,628 |
|
| Issue Date FY: 2010 ( Subtotal = $0 ) |
| | 2010 | 2009 | MAKSCIENTIFIC LLC | PO BOX 184 | WEST MYSTIC | CT | 06388 | SOUTHEASTERN CT | USA | R44DA023737 | New Drugs to Enhance Endocannabinoid Responses for Treating Excitotoxicity, Phase | 001 | 2 | NIH | 8/23/2010 | $0 |
| | 2010 | 2009 | MAKSCIENTIFIC LLC | PO BOX 184 | WEST MYSTIC | CT | 06388 | SOUTHEASTERN CT | USA | R44DA023737 | New Drugs to Enhance Endocannabinoid Responses for Treating Excitotoxicity, Phase | 000 | 2 | NIH | 2/24/2010 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $489,260 ) |
| | 2009 | 2009 | MAKSCIENTIFIC LLC | P.O. BOX 184 | WEST MYSTIC | CT | 06388-0184 | SOUTHEASTERN CT | USA | R44DA023737 | New Drugs to Enhance Endocannabinoid Responses for Treating Excitotoxicity, Phase | 000 | 2 | NIH | 8/4/2009 | $489,260 |
|
| Issue Date FY: 2007 ( Subtotal = $130,066 ) |
| | 2007 | 2007 | MAKSCIENTIFIC LLC | PO BOX 184 | WEST MYSTIC | CT | 06388 | SOUTHEASTERN CT | USA | R43DA023737 | NEW DRUGS TO ENHANCE ENDOCANNABINOID RESPONSES FOR TREATING EXCITOTOXICITY | 000 | 1 | NIH | 8/27/2007 | $130,066 |
|
| Issue Date FY: 2004 ( Subtotal = $154,017 ) |
| | 2004 | 2004 | MAKSCIENTIFIC LLC | 3 THOMAS STREET | MYSTIC | CT | 06355 | SOUTHEASTERN CT | USA | R43DA018031 | CB1 RECEPTOR ANTAGONISTS IN DRUG ABUSE | 000 | 1 | NIH | 9/29/2004 | $154,017 |
|
|
